Loading...
Loading...
Contributors:
Dataset URI:
10.1021/acs.jmedchem.6c00613.s003PSMA is an attractive theranostic target for prostate cancer (PCa). Inspired by the oral absorption enhancer SNAC, we report a novel strategy for optimizing PSMA-targeted radioligands via covalent SNAC conjugation distinct from conventional albumin-binding designs. Three SNAC-modified ligands (PSA3-1, PDA3-1, PDB3-1) bearing quinoline/naphthalene linkers were radiolabeled with 68Ga and 177Lu, affording high radiochemical purity (>98%) and hydrophilicity. PDB3-1 displayed the highest PSMA binding affinity (IC50 = 19.1 nM; docking score: −12.3 kcal/mol). In PC-3 PIP tumor-bearing mice, [68Ga]Ga-PDB3-1 PET revealed high tumor uptake with minimal background. Corresponding [177Lu]Lu-PDB3-1 biodistribution studies confirmed low systemic retention and rapid renal clearance. Therapy [177Lu]Lu-PDB3-1 achieved tumor inhibition and survival benefits comparable to [177Lu]Lu-PSMA-617, even at a reduced dose (9.25 MBq). High-tolerated dose studies (111 MBq) confirmed safety with unremarkable histopathology. These findings suggest that SNAC conjugation may represent a promising approach for the development of PSMA-targeted radiotheranostics for PCa.
Keyword(s):
[< sup; − 12; 111 mbq; 177; 25 mbq )..
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)